Comparison of Ocular and Developmental Outcomes in Laser-and Bevacizumab-treated Infants with Retinopathy of Prematurity
Lingkun Kong, Kimberly L. Dinh, Sid A. Schechet, David K. Coats, Robert G. Voigt, Ann B. Demny, Paul G. Steinkuller
Ophthalmology Research: An International Journal · pp. 13–22 · Published 27 Sep 2014
10.9734/OR/2015/13281Abstract
Purpose: To compare vision and developmental outcomes in infants who were treated with intravitreal bevacizumab injection (IVB) versus laser for retinopathy of prematurity (ROP). Methods: Forty-two infants were enrolled in this study and treated with either IVB at 0.625 mg per eye, per dose (22 patients, 43 eyes), or laser (20 patients, 37 eyes) for type I ROP. Systemic complications were compared between these two groups. Structural examinations and cycloplegic refractions were performed at age 1 year. Body weight gains were collected from birth to 36 weeks of postnatal age. Neurodevelopmental assessment was done at 1 year chronological age. Results: At 1 year of age, four eyes (10.8%) in the laser-treated group and none (0.0%) in the IVB-treated group had unfavorable structural outcome; ten (30%) eyes in the IVB-treated group and 17 (53%) eyes in the laser-treated group were myopic, p =0.03; the mean spherical equivalent was -0.03 diopter (D) in the IVB-treated group and -2.94 D in the laser-treated group, p=0.02. The mean visual acuity in LogMar was 0.54 (SD, 0.34) and 0.58 (SD, 0.52) in the IVB- and laser-treated groups, respectively (p=0.31). The average weekly weight gain continued at normal rates in both groups after treatment. Seven of ten patients (70%) in the IVB-treated group and six of nine patients (67%) in the laser-treated group were categorized as severely developmentally delayed. Conclusions: Bevacizumab intravitreal injection had similar short-term efficacy compared to laser treatment with regard to treatment of type I ROP but was associated with a lower prevalence of high myopia.
References (32)
- 1 Screening Examination of Premature Infants for Retinopathy of Prematurity [DOI]
- 2 Efficacy of Intravitreal Bevacizumab for Stage 3+ Retinopathy of Prematurity [DOI]
- 3 Infant mortality statistics from the 2004 period linked birth/infant death data set. [DOI]
- 4 Infant mortality statistics from the 2001 period linked birth/infant death data set.
- 5 Final results of the Early Treatment for Retinopathy of Prematurity (ETROP) randomized trial.
- 6 Screening Examination of Premature Infants for Retinopathy of Prematurity [DOI]
- 7 An update on progress and the changing epidemiology of causes of childhood blindness worldwide [DOI]
- 8 Serum Concentrations of Bevacizumab (Avastin) and Vascular Endothelial Growth Factor in Infants With Retinopathy of Prematurity [DOI]
- 9 Reactivation of Retinopathy of Prematurity After Bevacizumab Injection [DOI]
- 10 Neonatal weight loss in breast and formula fed infants [DOI]
- 11 Combination of laser photocoagulation and intravitreal bevacizumab (Avastin®) for aggressive zone I retinopathy of prematurity [DOI]
- 12 Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: a pilot study [DOI]
- 13 Outcome of Eyes Developing Retinal Detachment During the Early Treatment for Retinopathy of Prematurity Study [DOI]
- 14 Intravitreous Bevacizumab as Anti–Vascular Endothelial Growth Factor Therapy for Retinopathy of Prematurity: A Morphologic Study [DOI]
- 15 A Change in Oxygen Supplementation Can Decrease the Incidence of Retinopathy of Prematurity [DOI]
- 16 Multicenter trial of cryotherapy for retinopathy of prematurity: preliminary results. Cryotherapy for Retinopathy of Prematurity Cooperative Group.
- 17 Significant Treatment Failure With Intravitreous Bevacizumab for Retinopathy of Prematurity [DOI]
- 18 Weight change in the term baby in the first 2 weeks of life [DOI]
- 19 Growth patterns of low birth weight preterm infants: A longitudinal analysis of a large, varied sample [DOI]
- 20 Multicenter Trial of Cryotherapy for Retinopathy of Prematurity [DOI]
- 21 Diode laser treatment of posterior retinopathy of prematurity [DOI]
- 22 Intraventricular haemorrhage and its prognosis, prevention and treatment in term infants [DOI]
- 23 Combine intravitreal bevacizumab injection with laser treatment for aggressive posterior retinopathy of prematurity (AP-ROP).
- 24 Developmental and neurological progress of preterm infants with intraventricular haemorrhage and ventricular dilatation. [DOI]
- 25 Gesell and Amatruda's Developmental Diagnosis [DOI]
- 26 Follow-up of pre-term infants: is correction of the developmental quotient for prematurity helpful? [DOI]
- 27 PREDICTION OF DEATH AND MAJOR HANDICAP IN VERY PRETERM INFANTS BY BRAIN ULTRASOUND [DOI]
- 28 Blunted inflammatory and faster clinical recovery following laser treatment compared to cryotherapy.
- 29 On “Supplemental Therapeutic Oxygen for Prethreshold Retinopathy of Prematurity (STOP-ROP), a randomized, controlled trial. I: Primary outcomes” [DOI]
- 30 Gesell and Amatruda's Developmental Diagnosis [DOI]
- 31 Bevacizumab for Retinopathy of Prematurity [DOI]
- 32 Bevacizumab for retinopathy of prematurity. [DOI]
Cited by 12
Wei‐De Wang, Ya‐Hsin Yao, Chiao‐Hsin Lan · Acta Ophthalmologica · 2025
Georgios N. Tsiropoulos, Aikaterini K. Seliniotaki, Anna-Bettina Haidich · International Ophthalmology · 2022
Michael P. Blair, Sarah Hilkert Rodriguez, Sidney A. Schechet · A Quick Guide to Pediatric Retina · 2021
Monika Kaushal, Abdul Razak, Waseemoddin Patel · Journal of Perinatology · 2020
Showing 4 of 12 known citations — external sources report more than can currently be individually listed.
Related research
- Nitric Oxide Signaling in Developing Trigeminal Neurons — shares topic coverage
- Theaflavin Attenuates Hyperactivity and Cognitive Deficits in a Rodent Model of Prenatal Alcohol-induced ADHD — shares topic coverage
- From the Hierarchy of Abilities and Skills (HAS) to an Integrated Pediatric and Educational Therapies (IPET) Framework: A Conceptual Model for Assessment and Intervention — shares topic coverage
- Endocrinopathies in Paediatric Iron Deficiency Anaemia: Spectrum, Mechanisms, and Reversibility with Treatment — shares topic coverage
- The TEND Model: A Prefrontal Cortex Scaffold for Accelerating Adolescent Neurodevelopment and Mitigating the Legion Effect — shares topic coverage
Article metrics
Real usage data collected on this platform.
61
Page views
0
PDF downloads
28
Outbound clicks
12
Citations
Views over time
Views by country
Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".
Traffic sources
Referring site, by host.
Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.